Side-by-side comparison of AI visibility scores, market position, and capabilities
Chinese tech company with $37B revenue; world's third-largest smartphone maker entering EVs with Xiaomi SU7 after 88K first-day orders competing with BYD and Tesla in China.
Xiaomi is a Chinese multinational technology company producing smartphones, smart home devices, consumer electronics, and electric vehicles — known for offering near-premium performance at significantly lower prices than Apple and Samsung by relying on online-first distribution, thin margins, and MIUI ecosystem lock-in. Listed on the Hong Kong Stock Exchange (HKEX: 1810) and headquartered in Beijing, China, Xiaomi generates approximately ¥270 billion ($37 billion) in annual revenue and is the world's third-largest smartphone manufacturer by volume, with particular strength in China, India, and Southeast Asia.\n\nXiaomi's product ecosystem spans smartphones (Xiaomi, Redmi, POCO sub-brands targeting different price tiers), tablets, laptops, wearables (Mi Band fitness trackers), smart home devices (air purifiers, robot vacuums, smart plugs, cameras), and a growing electric vehicle lineup (Xiaomi SU7 sedan launched in 2024). The MIUI interface and HyperOS connect these devices into an integrated ecosystem. Xiaomi's sub-brand Redmi dominates value smartphone segments globally, while the flagship Mi series competes with Samsung's high-end Galaxy phones.\n\nIn 2025, Xiaomi has entered the electric vehicle market with the Xiaomi SU7 — an impressive first effort that received 88,000 orders in its first 24 hours of availability in China — signaling Xiaomi's ambition to become a comprehensive consumer technology platform company similar to Apple rather than just a smartphone maker. The EV entrance is Xiaomi's most significant strategic move in years, competing with BYD, Tesla China, and NIO in the premium Chinese EV market. Xiaomi's 2025 strategy focuses on SU7 production scaling, expanding premium smartphone market share globally, and growing its ecosystem of connected devices under HyperOS.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.